Metabotropic glutamate receptors in the pathophysiology and treatment of schizophrenia and major depression

Metabotropic Glutamate Receptors: Molecular Mechanisms, Role in Neurological Disorders and Pharmacological Effects

Volumn , Issue , 2014, Pages 73-105

  Newell, Kelly A ^a,b   Matosin, Natalie ^a,b   Lum, Jeremy S ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Antidepressant; Antipsychotic; Depression; GRM; Metabotropic glutamate receptor; MGlu; MGluR; Novel therapeutics; Pathophysiology; Schizophrenia

Indexed keywords

EID: 84931010930     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (159)

1. Weickert CS, Fung SJ, Catts VS, Schofield PR, Allen KM et al. (2013) Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Mol. Psychiatry 18:1185-1192.
2. Tokita K, Yamaji T, Hashimoto K (2012) Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol. Biochem. Behav. 100:688-704.
3. Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 263:367-377.
4. Matosin N, Newell KA (2013) Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci. Biobehav. Rev. 37:256-268.
5. Lesage A, Steckler T (2010) Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness. Eur. J. Pharmacol. 639:2-16.
6. Lavreysen H, Pereira SN, Leysen JE, Langlois X, Lesage ASJ (2004) Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]R214127. Neuropharmacology 46:609-619.
7. Zysk JR, Spear N, Fieles W, Stein MM, Sygowski LS, et al. (2013) In vitro binding of a radio-labeled positive allosteric modulator for metabotropic glutamate receptor subtype 5. Synapse 67:135-144.
8. Volk DW, Eggan SM, Lewis DA (2010) Alterations in metabotropic glutamate receptor 1a and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. Am. J. Psychiatry 167:1489-1498.
9. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL et al. (2005) Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57:123-131.
10. Ayoub MA, Angelicheva D, Vile D, Chandler D, Morar B et al. (2012) Deleterious GRM1 mutations in schizophrenia. PLoS ONE 7:e32849.
11. Frank RAW, McRae AF, Pocklington AJ, van de Lagemaat LN, Navarro P et al. (2011) Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder. PLoS ONE 6:e19011.
12. Brody SA, Conquet F, Geyer MA (2003) Disruption of prepulse inhibition in mice lacking mGluR1. Eur. J. Neurosci. 18:3361-3366.
13. Matosin N, Frank E, Deng C, Huang X-F, Newell KA (2013) Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment. Schizophr. Res. 146:170-176.
14. Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I et al. (2011) Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. J. Psychiatr. Res. 45:234-241.
15. Engmann O, Hortobágyi T, Pidsley R, Troakes C, Bernstein H-G et al. (2011) Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition. Brain 134:2408-2421.
16. Szumlinski KK, Lominac KD, Kleschen MJ, Oleson EB, Dehoff MH et al. (2005) Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav 4:273-288.
17. Iasevoli F, Tomasetti C, de Bartolomeis A (2012) Scaffolding proteins of the postsynaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases. Neurochem. Res. 38:1-22.
18. Thomas U (2002) Modulation of synaptic signalling complexes by Homer proteins. J. Neurochem. 81:407-413.
19. Mion S, Corti C, Neki A, Shigemoto R, Corsi M et al. (2001) Bidirectional regulation of neurite elaboration by alternatively spliced metabotropic glutamate receptor 5 (mGluR5) isoforms. Mol. Cell Neurosci. 17:957-972.
20. Joly C, Gomeza J, Brabet I, Curry K, Bockaert J et al. (1995) Molecular, functional, and pharmacological characterization of the metabotropic glutamate receptor type 5 splice variants: comparison with mGluR1. J. Neurosci. 15:3970-3981.
21. Newell KA (2013) Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs. Future Med. Chem. 5:1471-1474.
22. Mao L-M, Liu X-Y, Zhang G-C, Chu X-P, Fibuch EE et al. (2008) Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo. Neuropharmacology 55:403-408.
23. Orlando LR, Dunah AW, Standaert DG, Young AB (2002) Tyrosine phosphorylation of the metabotropic glutamate receptor mGluR5 in striatal neurons. Neuropharmacology 43:161-173.
24. Kozlovsky N, Scarr E, Dean B, Agam G (2006) Postmortem brain calcineurin protein levels in schizophrenia patients are not different from controls. Schizophr. Res. 83:173-177.
25. Wang H, Westin L, Nong Y, Birnbaum S, Bendor J et al. (2009) Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling. Science 326:1554-1557.
26. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD et al. (2003) Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc. Natl. Acad. Sci. 100:8987-8992.
27. Timms AE, Dorschner MO, Wechsler J, Choi KY, Kirkwood R, et al. (2013) Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry ll:1-9.
28. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B et al. (2012) Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol. Psychiatry 17:887-905.
29. Gray L, van den Buuse M, Scarr E, Dean B, Hannan AJ (2009) Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol. 12:45-60.
30. 11C] ABP688 PET and postmortem study. Am. J. Psychiatry 168:727.
31. Matosin N, Fernandez-Enright F, Frank E, Deng C, Wong J et al. (2013) Metabotropic glutamate receptor 2/3 and 5 in schizophrenia and allied mood disorders: evidence supporting mGluR-based therapeutics. 12th Biennial Australasian Schizophrenia Conference. Melbourne, Australia.
32. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B (2009) Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 33:70-75.
33. Rietschel M, Mattheisen M, Frank J, Treutlein J, Degenhardt F et al. (2010) Genomewide association-, replication-, and neuroimaging study implicates HOMER1 in the etiology of major depression. Biol. Psychiatry 68:578-585.
34. Kovacevic T, Skelin I, Minuzzi L, Rosa-Neto P, Diksic M (2012) Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: An autoradiographic study. Brain Res. Bull. 87:406-412.
35. Wieronska JM, Legutko B, Dudys D, Pilc A (2008) Olfactory bulbectomy and amitriptyline treatment influences mGlu receptors expression in the mouse brain hippocampus. Pharmacol. Rep. 60:844-855.
36. Menke A, Sämann P, Kloiber S, Czamara D, Lucae S et al. (2012) Polymorphisms within the metabotropic glutamate receptor 1 gene are associated with depression phenotypes. Psychoneuroendocrinology 37:565-575.
37. Kew JNC, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 179:4-29.
38. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, et al. (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav. Pharmacol. 14:257.
39. Harrison PJ, Lyon L, Sartorius LJ, Burnet P, Lane TA (2008) Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J. Psychopharmacol. 22:308-322.
40. Lian J, Huang X-F, Pai N, Deng C (2013) Effects of olanzapine and betahistine cotreatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density. Prog. Neuropsychopharmacol. Biol. Psychiatry 47:62-68.
41. Miller JM, Hesselgrave N, Ogden RT, Zanderigo F, Oquendo MA et al. (2013) Brain serotonin 1A receptor binding as a predictor of treatment outcome in major depressive disorder. Biol. Psychiatry 74:760-767.
42. Frank E, Newell KA, Huang XF (2011) Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age. Schizophr. Res. 128:56-60.
43. Corti C, Crepaldi L, Mion S, Roth AL, Xuereb JH et al. (2007) Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol. Psychiatry 62:747-755.
44. Ghose S, Gleason KA, Potts BW, Lewis-Amezcua K, Tamminga CA (2009) Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am. J. Psychiatry 166:812-820.
45. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452:93-97.
46. Chen Q, He G, Chen Q, Wu S, Xu Y, et al. (2005) A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr. Res. 73:21-26.
47. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH et al. (2004) Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. 101:12604-12609.
48. Fujii Y, Shibata H, Kikuta R, Makino C, Tani A et al. (2003) Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr. Genet. 13:71-76.
49. Marti SB, Cichon S, Propping P, Nothen M (2002) Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am. J. Med. Genet. 114:46-50.
50. Norton N, Williams HJ, Dwyer S, Ivanov D, Preece AC et al. (2005) No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 5:23.
51. Tochigi M, Suga M, Ohashi J, Otowa T, Yamasue H et al. (2006) No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population. Schizophr. Res. 88:260-264.
52. Baune BT, Suslow T, Beste C, Birosova E, Domschke K et al. (2010) Association between genetic variants of the metabotropic glutamate receptor 3 (GRM3) and cognitive set shifting in healthy individuals. Genes Brain Behav. 9:459-466.
53. Bishop JR, Ellingrod VL, Moline J, Miller D (2005) Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr. Res. 77:253-260.
54. Tascedda F, Blom JMC, Brunello N, Zolin K, Gennarelli M et al. (2001) Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol. Psychiatry 50:117-122.
55. Zhao J, Bao A-M, Qi X-R, Kamphuis W, Luchetti S et al. (2012) Gene expression of GABA and glutamate pathway markers in the prefrontal cortex of non-suicidal elderly depressed patients. J. Affect. Disord. 138:494-502.
56. Feyissa AM, Woolverton WL, Miguel-Hidalgo JJ, Wang Z, Kyle PB et al. (2010) Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 34:279-283.
57. Tsunoka T, Kishi T, Ikeda M, Kitajima T, Yamanouchi Y et al. (2009) Association analysis of Group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog. Neuropsychopharmacol. Biol. Psychiatry 33:875-879.
58. Kawasaki T, Ago Y, Yano K, Araki R, Washida Y et al. (2011) Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice. Neuropharmacology 60:397-404.
59. Matrisciano F, Caruso A, Orlando R, Marchiafava M, Bruno V et al. (2008) Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats. Neuropharmacology 55:525-531.
60. Kaffman A, Krystal JJ (2012) New Frontiers in Animal Research of Psychiatric Illness. In: Kobeissy FH (ed) Psychiatric Disorders. Totowa, NJ: Humana Press, Vol. 829. pp. 3-30.
61. Nakajima Y, Iwakabe H, Akazawa C, Nawa H, Shigemoto R et al. (1993) Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J. Biol. Chem. 268:11868-11873.
62. Pilc A, Wieronska JM, Skolnick P (2013) Glutamate-based antidepressants: preclinical psychopharmacology. Biol. Psychiatry 73:1125-1132.
63. Shigemoto R, Kulik A, Roberts JD, Ohishi H, Nusser Z et al. (1996) Target-cellspecific concentration of a metabotropic glutamate receptor in the presynaptic active zone. Nature 381:523-525.
64. Makoff A, Lelchuk R, Oxer M, Harrington K, Emson P (1996) Molecular characterization and localization of human metabotropic glutamate receptor type 4. Mol. Brain Res. 37:239-248.
65. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH (2000) Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol. Psychiatry 47:22-28.
66. Shibata H, Tani A, Chikuhara T, Kikuta R, Sakai M et al. (2009) Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Res. 167:88-96.
67. Ohtsuki T, Toru M, Arinami T (2001) Mutation screening of the metabotropic glutamate receptor mGluR4 (GRM4) gene in patients with schizophrenia. Psychiatr. Genet. 11:79-83.
68. Iscru E, Goddyn H, Ahmed T, Callaerts-Vegh Z, D'Hooge R et al. (2013) Improved spatial learning is associated with increased hippocampal but not prefrontal long-term potentiation in mGluR4 knockout mice. Genes Brain Behav. 12:615-625.
69. O'Connor RM, Pusceddu MM, Dinan TG, Cryan JF (2013) Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: Effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment. Neuropharmacology 66:236-241.
70. Okamoto N, Hori S, Akazawa C, Hayashi Y, Shigemoto R et al. (1994) Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction. J. Biol. Chem. 269:1231-1236.
71. Makoff A, Pilling C, Harrington K, Emson P (1996) Human metabotropic glutamate receptor type 7: molecular cloning and mRNA distribution in the CNS. Brain Res. Mol. Brain Res. 40:165-170.
72. Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299:12-20.
73. Ohtsuki T, Koga M, Ishiguro H, Horiuchi Y, Arai M et al. (2008) A polymorphism of the metabotropic glutamate receptor mGluR7 (GRM7) gene is associated with schizophrenia. Schizophr. Res. 101:9-16.
74. Ganda C, Schwab SG, Amir N, Heriani H, Irmansyah I et al. (2009) A family-based association study of DNA sequence variants in GRM7 with schizophrenia in an Indonesian population. Int. J. Neuropsychopharmacol. 12:1283-1289.
75. Bolonna AA, Kerwin RW, Munro J, Arranz MJ, Makoff AJ (2001) Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. Schizophr. Res. 47:99-103.
76. Callaerts-Vegh Z, Beckers T, Ball SM, Baeyens F, Callaerts PF et al. (2006) Concomitant deficits in working memory and fear extinction are functionally dissociated from reduced anxiety in metabotropic glutamate receptor 7-deficient mice. J. Neurosci. 26:6573-6582.
77. Hikichi H, Murai T, Okuda S, Maehara S, Satow A et al. (2010) Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents. Eur. J. Pharmacol. 639:106-114.
78. Wieronska JM, Branski P, Siwek A, Dybala M, Nowak G et al. (2010) GABAergic dysfunction in mGlu7 receptor-deficient mice as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and increased reelin proteins in the hippocampus. Brain Res. 1334:12-24.
79. Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P et al. (2011) Hippocampal interneurons are abnormal in schizophrenia. Schizophr. Res. 131:165-173.
80. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA et al. (2011) Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol. Psychiatry 16:202-215.
81. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ et al. (2003) Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur. J. Neurosci. 17:2409-2417.
82. Mitsukawa K, Mombereau C, Lötscher E, Uzunov DP, van der Putten H et al. (2005) Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. Neuropsychopharmacology 31:1112-1122.
83. Palucha A, Klak K, Branski P, Putten H, Flor PJ et al. (2007) Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology 194:555-562.
84. O'Mahony CM, Bravo JA, Dinan TG, Cryan JF (2010) Comparison of hippocampal metabotropic glutamate receptor 7 (mGlu7) mRNA levels in two animal models of depression. Neurosci. Lett. 482:137-141.
85. Corti C, Restituito S, Rimland JM, Brabet I, Corsi M, et al. (1998) Cloning and characterization of alternative mRNA forms for the rat metabotropic glutamate receptors mGluR7 and mGluR8. Eur. J. Neurosci. 10:3629-3641.
86. Saugstad JA, Kinzie JM, Shinohara MM, Segerson TP, Westbrook GL (1997) Cloning and expression of rat metabotropic glutamate receptor 8 reveals a distinct pharmacological profile. Mol. Pharmacol. 51:119-125.
87. Takaki H, Kikuta R, Shibata H, Ninomiya H, Tashiro N et al. (2004) Positive associations of polymorphisms in the metabotropic glutamate receptor type 8 gene (GRM8) with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128B:6-14.
88. Robbins MJ, Starr KR, Honey A, Soffin EM, Rourke C et al. (2007) Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res. 1152:215-227.
89. Linden A-M, Johnson B., Peters S., Shannon H., Tian M et al. (2002) Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology 43:251-259.
90. O'Connor RM, Pusceddu MM, O'Leary OF, Savignac HM, Bravo JA et al. (2013) Hippocampal group III mGlu receptor mRNA levels are not altered in specific mouse models of stress, depression and antidepressant action. Pharmacol. Biochem. Behav. 103:561-567.
91. Terracciano A, Tanaka T, Sutin AR, Sanna S, Deiana B, et al. (2010) Genome-wide association scan of trait depression. Biol. Psychiatry 68:811-817.
92. Fatemi SH, Folsom TD, Rooney RJ, Thuras PD (2013) mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl. Psychiatry 3:e271.
93. Corti C, Xuereb JH, Crepaldi L, Corsi M, Michielin F et al. (2011) Altered levels of glutamatergic receptors and Na+/K+ ATPase-a1 in the prefrontal cortex of subjects with schizophrenia. Schizophr. Res. 128:7-14.
94. Sartorius LJ, Weinberger DR, Hyde TM, Harrison PJ, Kleinman JE et al. (2008) Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology 33:2626-2634.
95. Crook JM, Akil M, Law BCW, Hyde TM, Kleinman JE (2002) Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol. Psychiatry 7:157-164.
96. Ohnuma T, Tessler S, Arai H, Faull RLM, McKenna PJ, et al. (2000) Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Mol. Brain Res. 85:24-31.
97. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC (1998) Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol. Brain Res. 56:207-217.
98. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 27:1081-1090.
99. Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J et al. (2010) Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology 212:329-344.
100. Kammermeier PJ, Worley PF (2007) Homer 1a uncouples metabotropic glutamate receptor 5 from postsynaptic effectors. Proc. Natl. Acad. Sci. 104:6055-6060.
101. Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev. 61:105-123.
102. Śmialowska M, Szewczyk B, Branski P, Wieronska JM, Palucha A et al. (2002) Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 42:1016-1023.
103. Matrisciano F, Storto M, Ngomba RT, Cappuccio I, Caricasole A et al. (2002) Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology 42:1008-1015.
104. Musazzi L, Treccani G, Mallei A, Popoli M (2013) The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol. Psychiatry 73:1180-1188.
105. Zahorodna A, Bijak M (1999) An antidepressant-induced decrease in the responsiveness of hippocampal neurons to group I metabotropic glutamate receptor activation. Eur. J. Pharmacol. 386:173-179.
106. Hughes ZA, Neal SJ, Smith DL, Sukoff Rizzo SJ, Pulicicchio CM et al. (2013) Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 66:202-214.
107. Molinaro G, Traficante A, Riozzi B, Menna LD, Curto M et al. (2009) Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice. Mol. Pharmacol. 76:379-387.
108. Palłucha A, Brański P, Kĺak K, Sowa M (2007) Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity. Pharmacol. Rep. 59:525-530.
109. Wierońska JM, Klak K, Palucha A, Branski P, Pilc A (2007) Citalopram influences mGlu7, but not mGlu4 receptors' expression in the rat brain hippocampus and cortex. Brain Res. 1184:88-95.
110. Weston-Green K, Huang X-F, Deng C (2013) Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. CNS Drugs 27:1069-1080.
111. Geddes AE, Huang XF, Newell KA (2011) Reciprocal signalling between NR2 subunits of the NMDA receptor and Neuregulin1 and their role in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 4:896-904.
112. Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P et al. (2013) Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr. Top Med. Chem. 13:26-54.
113. Vinson P, Conn JP (2012) Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 62:1461-1472.
114. Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66:522-526.
115. Moghaddam B, Krystal JH (2012) Capturing the angel in angel dust: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr. Bull. 38:942-949.
116. Biber K, Laurie DJ, Berthele A, Sommer B, Tölle TR et al. (1999) Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem. 72:1671-1680.
117. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J et al. (2013) Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol. Psychiatry 18:206-214.
118. Byrnes KR, Stoica B, Loane DJ, Riccio A, Davis MI et al. (2009) Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 57:550-560.
119. Loane DJ, Stoica BA, Pajoohesh-Ganji A, Byrnes KR, Faden AI (2009) Activation of metabotropic glutamate receptor 5 modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase. J. Biol. Chem. 284:15629-15639.
120. Ohta H, Kawamoto H, Suzuki G (2010) mGluR1 negative allosteric modulators: an alternative metabotropic approach for the treatment of schizophrenia. In: Skolnick P (ed). Glutamate-based Therapies for Psychiatric Disorders. Milestones in Drug Therapy. Springer. pp. 117-131.
121. De Vry J, Horváth E, Schreiber R (2001) Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu1 receptor antagonist BAY 36-7620. Eur. J. Pharmacol. 428:203-214.
122. Pietraszek M, Gravius A, Schafer D, Weil T, Trifanova D et al. (2005) mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49:73-85.
123. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY (2007) Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur. Neuropsychopharmacol. 17:172-179.
124. Rosenbrock H, Kramer G, Hobson S, Koros E, Grundl M et al. (2010) Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator. Eur. J. Pharmacol. 639:40-46.
125. Gastambide F, Gilmour G, Robbins TW, Tricklebank MD (2013) The mGlu5 positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat. Neuropharmacology 64:240-247.
126. Gastambide F, Cotel M-C, Gilmour G, O'Neill MJ, Robbins TW et al. (2012) Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacol. 37:1057-1066.
127. Gilmour G, Broad LM, Wafford KA, Britton T, Colvin EM et al. (2013) In vitro characterisation of the novel positive allosteric modulators of the mGlu5 receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology 64:224-239.
128. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN et al. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther. 309:568-577.
129. Zhang Y, Rodriguez AL, Conn PJ (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 315:1212-1219.
130. Noetzel MJ, Gregory KJ, Vinson PN, Manka JT, Stauffer SR et al. (2013) A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol. Pharmacol. 83:835-847.
131. Ayala JE, Chen Y, Banko JL, Sheffler DJ, Williams R et al. (2009) mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 34:2057-2071.
132. Pecknold JC, McClure DJ, Appeltauer L, Wrzesinski L, Allan T (1982) Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 2:129-133.
133. Liu CY, Jiang XX, Zhu YH, Wei DN (2012) Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: Role of brain-derived neurotrophic factor. Neuroscience 223:219-224.
134. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS et al. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharmacol. 78:1105-1123.
135. Fell MJ, McKinzie DL, Monn JA, Svensson KA (2012) Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology 62:1473-1483.
136. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N et al. (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179:303-309.
137. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat. Med. 13:1102-1107.
138. Kinon B, Zhang L, Millen B, Osuntokun O, Williams J, et al. (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol. 31:349-355.
139. Liu W, Downing ACM, Munsie LM, Chen P, Reed MR et al. (2012) Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. Pharmacogenomics J. 12:246-254.
140. Galici R, Echemendia NG, Rodriguez AL, Conn PJ (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315:1181-1187.
141. Chaki S, Ago Y, Palucha-Paniewiera A, Matrisciano F, Pilc A (2013) mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. Neuropharmacology 66:40-52.
142. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M et al. (2004) MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46:457-467.
143. Dwyer JM, Lepack AE, Duman RS (2013) mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J. Mol. Psychiatry 1:15.
144. Koike H, Iijima M, Chaki S (2013) Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol. Biochem. Behav. 107:20-23.
145. Campo B, Kalinichev M, Lambeng N, El Yacoubi M, Royer-Urios I et al. (2011) Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J. Neurogenet. 25:152-166.
146. Karasawa J, Shimazaki T, Kawashima N, Chaki S (2005) AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res. 1042:92-98.
147. Yoshimizu T, Shimazaki T, Ito A, Chaki S (2006) An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology 186:587-593.
148. Palłucha-Poniewiera A, Wierońska JM, Branski P, Stachowicz K, Chaki S et al. (2010) On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology 212:523-535.
149. Vizi E, Fekete A, Karoly R, Mike A (2010) Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. Br. J. Pharmacol. 160:785-809.
150. Wierońska JM, Stachowicz K, Acher F, Lech T, Pilc A (2011) Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology 220:481-494.
151. Slławinska A, Wierońska JM, Stachowicz K, Marciniak M, Lłasoń-Tyburkiewicz M et al. (2013) The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents. Br. J. Pharmacol. 169:1824-1839.
152. Wierońska JM, Acher FC, Slławińska A, Gruca P, Lłasoń-Tyburkiewicz M et al. (2013) The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signalling. Psychopharmacology 227:711-725.
153. Bradley SR, Uslaner JM, Flick RB, Lee A, Groover KM et al. (2012) The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling. Pharmacol. Biochem. Behav. 101:35-40.
154. Sukoff Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL et al. (2011) The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J. Pharmacol. Exp. Ther. 338:345-352.
155. Klakotskaia D, Ramsey AK, Fowler SW, Serfozo P, Simonyi A et al. (2013) Effects of group II and III metabotropic glutamate receptor ligands on conditioned taste aversion learning. Behav. Brain Res. 253:9-16.
156. Palucha-Poniewiera A, Pilc A (2013) A selective mGlu7 receptor antagonist MMPIP reversed antidepressant-like effects of AMN082 in rats. Behav. Brain Res. 238:109-112.
157. O'Connor RM, Cryan JF (2013) The effects of mGlu7 receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains: Behav. Pharmacol. 24:105-113.
158. Buckley PF, Miller BJ, Lehrer DS, Castle DJ (2009) Psychiatric Comorbidities and Schizophrenia. Schizophr. Bull. 35:383-402.
159. Filippich C, Wolvetang EJ, Mowry BJ (2013) Will brain cells derived from induced pluripotent stem cells or directly converted from somatic cells (iNs) be useful for schizophrenia research? Schizophr. Bull. 39:948-954.